European Archives - Page 926 of 1151 - European Medical Journal

Study Results: Titanium-Nitride-Oxide (TiNO) Coated Stent Is Non-Inferior to Bioabsorbable Polymer Everolimus-Eluting Stent (EES), for Patients Presenting with Acute Coronary Syndrome (ACS)

Barcelona, 29 August, 2017 – During the Late Breaking Science session at the European Society of Cardiology (ESC) Congress in Barcelona, Dr. Pim Tonino…

EMJ

EULAR 2017 – Interview – Dr João Fonseca

An interview with Dr João Fonseca (Lisbon Academic Medical Centre, Portugal) at this year’s EULAR congress held in Madrid, Spain.

EHA – 2017 – Congress Highlights

Grab our full congress review of EHA 2017 in EMJ’s Hematology 5.1 eJournal. In the meantime take a look at this year’s congress highlights.

EMJ

EHA 2017 – Opening Ceremony

Our full congress review of EHA 2017 is now available for free in our Hematology 5.1 eJournal, and here is a look at the opening ceremony.

EAACI 2017 – Interview – Prof Maria Jose Torres

An interview with Prof Maria Jose Torres (Malaga Regional University Hospital, Spain) at this year’s EAACI congress held in Helsinki, Finland.

EAACI 2017 – Interview – Dr Enrico Heffler

An interview with Dr Enrico Heffler (Humanitas University, Italy) at this year’s EAACI congress held in Helsinki, Finland.

The Potential of Immune Cells to Treat Allergy and Infection

SUCCESSFUL allergy and infection therapies may be possible following recent insights into the development and function of newly discovered Type 1…

Reducing the Harmful Effects of Immune Cells

DISRUPTION of a key enzyme involved in immune cell-mediated damage has been researchers’ focus, in the hope of discovering a novel treatment target for a…

Mesothelioma: A Dormant Threat

The industrialised world is truly a marvel; through years of innovation and invention, society has been rewarded with extreme technological advances.

Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse

Immatics announced enrolment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101.